Straits Times Index
3,296.89 +4.20 (+0.13%) S&P 500
5,064.20 +45.81 (+0.91%) Dow
38,225.66 +322.37 (+0.85%) Nasdaq
15,840.96 +235.48 (+1.51%) Bitcoin USD
59,080.03 +676.61 (+1.16%) CMC Crypto 200
1,274.71 +3.96 (+0.31%)
KORU Medical Systems, Inc. (KRMD)
After hours:
| Previous close | 2.2500 |
| Open | 2.2700 |
| Bid | 2.3300 x 100 |
| Ask | 2.4400 x 100 |
| Day's range | 2.2700 - 2.4700 |
| 52-week range | 1.9780 - 4.2950 |
| Volume | |
| Avg. volume | 102,291 |
| Market cap | 110.844M |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
KORU Medical Systems, Inc. Announces 2024 First Quarter Financial Results Delivering Double-Digit Revenue Growth
MAHWAH, N.J., May 01, 2024--KORU Medical Systems, Inc. (NASDAQ: KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today reported financial results for the first quarter ended March 31, 2024.
- Business Wire
KORU Medical Systems to Report First Quarter 2024 Financial Results on May 1, 2024
MAHWAH, N.J., April 17, 2024--KORU Medical Systems (NASDAQ: KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced that the Company will report first quarter 2024 financial results on Wednesday, May 1, 2024. KORU Medical’s management will host a conference call and webcast at 4:30 p.m. ET that day to discuss the financ
- Business Wire
KORU Medical Systems Announces Successful Appeal in EU Notified Body Review
MAHWAH, N.J., April 11, 2024--KORU Medical Systems, Inc. (NASDAQ: KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous infusion solutions, today announced a successful appeal related to an ongoing audit by its notified body in the EU, The British Standards Institute (BSI).
